Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 2/20 | 0.37 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.33 |
| ▸ | METAP1 | P53582 | 2/20 | 0.33 |
| ▸ | METAP2 | P50579 | 1/20 | 0.33 |
| ▸ | CBFB | Q13951 | 1/20 | 0.33 |
| ▸ | GUSB | P08236 | 1/20 | 0.32 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9384373 | 0.81 | AURKA (0.39) | AURKAAURKBPDE4APDE4BPDE4C | |
| SCHEMBL5314664 | 0.79 | AURKA (0.37) | AURKAAURKBARPDE4APDE4B | |
| SCHEMBL9382130 | 0.78 | AURKA (0.47) | AURKAAURKBPDE4APDE4BPDE4C | |
| SCHEMBL10555120 | 0.78 | NPC1 (0.47) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| Hydrochloric Acid SCHEMBL10554384 | 0.76 | AR (0.42) | AURKAAURKBARPDE4APDE4B | |
| SCHEMBL2455602 | 0.76 | PDE4A (0.57) | ARPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4918102 | 0.75 | METAP1 (0.49) | METAP1METAP2CBFBGUSB | |
| SCHEMBL5619649 | 0.75 | METAP1 (0.34) | AURKAAURKBARMETAP1METAP2 | |
| Hydrochloric Acid SCHEMBL10555631 | 0.75 | NPC1 (0.46) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL10556856 | 0.75 | AR (0.36) | AURKAAURKBARPDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2008514565-A | — | — | 2008-05-08 | — | — | JP | claimed |
| US-7285569-B2 | Tricycles, their manufacture and use as pharmaceutical agents | HOFF HOFFMANN-LA ROCHE INC. (US) | 2007-10-23 | — | — | US | claimed |
| EP-1793822-A1 | TRICYCLES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. Hoffmann-Roche AG (CH) | 2007-06-13 | — | — | EP | claimed |
| WO-2006032519-A1 | TRICYCLES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-03-30 | — | — | WO | claimed |
| US-7285569-B2 | Tricycles, their manufacture and use as pharmaceutical agents | HOFF HOFFMANN-LA ROCHE INC. (US) | 2007-10-23 | — | — | US | disclosed |
| EP-1793822-A1 | TRICYCLES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. Hoffmann-Roche AG (CH) | 2007-06-13 | — | — | EP | disclosed |
| WO-2006032519-A1 | TRICYCLES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-03-30 | — | — | WO | disclosed |
| US-20060069145-A1 | Tricycles, their manufacture and use as pharmaceutical agents | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069145-A1 | Tricycles, their manufacture and use as pharmaceutical agents | ABCB1, CYP3A43, CYP3A5 | AURKA 1724/4885AURKB 1606/4885AR 1883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.